Hinrich Abken spends much of his time researching T cell, Antigen, Chimeric antigen receptor, Molecular biology and Cytotoxic T cell. His T cell study introduces a deeper knowledge of Immunology. His research in Antigen intersects with topics in Receptor, Cancer research and CD30.
Hinrich Abken is investigating Chimeric antigen receptor as part of his inquiry into Immunotherapy and Immune system. Hinrich Abken has researched Molecular biology in several fields, including Major histocompatibility complex, Transfection and T-cell receptor. Epitope is closely connected to CD8 in his research, which is encompassed under the umbrella topic of Cell biology.
Hinrich Abken mostly deals with Immunology, T cell, Antigen, Chimeric antigen receptor and Cancer research. His Cytotoxic T cell research extends to Immunology, which is thematically connected. He focuses mostly in the field of T cell, narrowing it down to topics relating to Cell biology and, in certain cases, Secretion.
His Antigen research is multidisciplinary, incorporating perspectives in Receptor, Molecular biology, Adoptive cell transfer, T-cell receptor and Antibody. His studies in Chimeric antigen receptor integrate themes in fields like Cancer cell, Leukemia, Cell therapy and Virology. His Cancer research research incorporates themes from Natural killer cell, Car t cells and B cell.
His primary areas of investigation include Chimeric antigen receptor, Cancer research, Cell biology, Cell therapy and T cell. His biological study spans a wide range of topics, including CD28, Cell, Leukemia and Cytokine. The concepts of his Cancer research study are interwoven with issues in IL-2 receptor, Immune system, B cell and Epitope, Antigen.
His IL-2 receptor study combines topics from a wide range of disciplines, such as Natural killer T cell, Interleukin 21 and Antigen-presenting cell. His work carried out in the field of Cell biology brings together such families of science as Luciferase and Bacteria. His T cell research is under the purview of Immunology.
Chimeric antigen receptor, Cancer research, Cell therapy, T cell and Immunotherapy are his primary areas of study. His Chimeric antigen receptor research incorporates elements of Leukemia, Cytokine, CD19 and Cell biology. Hinrich Abken has included themes like B cell, Interleukin 12 and Antigen in his Cancer research study.
Hinrich Abken works mostly in the field of Antigen, limiting it down to topics relating to Car t cells and, in certain cases, Cell, as a part of the same area of interest. His Cell therapy study combines topics in areas such as Transforming growth factor, Psychological repression and Immune system. His T cell study is concerned with the larger field of Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
Markus Chmielewski;Caroline Kopecky;Andreas A. Hombach;Hinrich Abken.
Cancer Research (2011)
TRUCKs: the fourth generation of CARs.
Markus Chmielewski;Hinrich Abken.
Expert Opinion on Biological Therapy (2015)
Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
Andreas Hombach;Anja Wieczarkowiecz;Thomas Marquardt;Claudia Heuser.
Journal of Immunology (2001)
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
Markus Chmielewski;Andreas A. Hombach;Hinrich Abken.
Immunological Reviews (2014)
T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain above Threshold Does Not Increase T Cell Activation against Antigen-Positive Target Cells but Decreases Selectivity
Markus Chmielewski;Andreas Hombach;Claudia Heuser;Gregory P. Adams.
Journal of Immunology (2004)
CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
Markus Chmielewski;Hinrich Abken.
Cell Reports (2017)
Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
Barbara Savoldo;Cliona M. Rooney;Cliona M. Rooney;Antonio Di Stasi;Hinrich Abken.
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
A Hombach;A A Hombach;H Abken.
Gene Therapy (2010)
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.
Andreas A. Hombach;Johannes Heiders;Marcel Foppe;Markus Chmielewski.
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
David E. Gilham;Reno Debets;Martin Pule;Robert E. Hawkins.
Trends in Molecular Medicine (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: